Nuzenio

Plaque Psoriasis

Plaque Psoriasis news intelligence with latest source-attributed stories, timeline, related explainers, connected entities, source diversity, and FAQ.

topic 6 latest news signals 3 publisher sources 100/100 entity strength

Latest news

Socrodeucitinib Meets Primary Endpoint in Phase 2 Psoriasis Study - HCPLiveHCPLive · Fri, 07 Aug 2026 23:10:36 GMTOral TYK2 Inhibitor Socrodeucitinib Meets Primary Endpoint in Phase 2 Psoriasis Trial - Dermatology TimesDermatology Times · Fri, 07 Aug 2026 16:04:43 GMTTreating Adolescent Plaque Psoriasis: Tolerability and Adherence - HCPLiveHCPLive · Fri, 07 Aug 2026 12:11:05 GMTOral Therapy Evolution in Plaque Psoriasis: From PDE4 to Peptides - HCPLiveHCPLive · Fri, 31 Jul 2026 16:04:07 GMTBreaking the Topical Cycle in Plaque Psoriasis Management - HCPLiveHCPLive · Fri, 31 Jul 2026 16:04:07 GMTFirst Oral IL-23 Blocker Gets EMA Nod for Plaque Psoriasis - MedscapeMedscape · Tue, 28 Jul 2026 11:42:38 GMT

Timeline

Fri, 07 Aug 2026 23:10:36 GMTSocrodeucitinib Meets Primary Endpoint in Phase 2 Psoriasis Study - HCPLive
Fri, 07 Aug 2026 16:04:43 GMTOral TYK2 Inhibitor Socrodeucitinib Meets Primary Endpoint in Phase 2 Psoriasis Trial - Dermatology Times
Fri, 07 Aug 2026 12:11:05 GMTTreating Adolescent Plaque Psoriasis: Tolerability and Adherence - HCPLive
Fri, 31 Jul 2026 16:04:07 GMTOral Therapy Evolution in Plaque Psoriasis: From PDE4 to Peptides - HCPLive
Fri, 31 Jul 2026 16:04:07 GMTBreaking the Topical Cycle in Plaque Psoriasis Management - HCPLive
Tue, 28 Jul 2026 11:42:38 GMTFirst Oral IL-23 Blocker Gets EMA Nod for Plaque Psoriasis - Medscape

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Plaque Psoriasis.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

3 distinct publisher/source names are currently connected to this entity page.